AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18823217 — intervention group
Group type: COMPARATOR
Intervention: Etravirine 100 mg after a light breakfast (croissant)
Number of subjects: 24
Study 18823217 — intervention group
Group type: COMPARATOR
Intervention: Etravirine 100 mg after an enhanced-fiber breakfast
Number of subjects: 24
Study 18823217 — intervention group
Group type: COMPARATOR
Intervention: Etravirine 100 mg after a high-fat breakfast
Number of subjects: 24
Study 19116438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (5 days/week for 3 weeks)
Number of subjects: 10
Study 19116438 — intervention group
Group type: COMPARATOR
Intervention: Control group (ambient air)
Number of subjects: 10
Study 14724827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily 1 week before chemotherapy (group 1)
Number of subjects: 30
Study 14724827 — intervention group
Group type: COMPARATOR
Intervention: Deferred lamivudine treatment until serological evidence of hepatitis B virus reactivation (group 2)
Number of subjects: 30
Study 14724827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment (group 1)
Number of subjects: 30
Study 11930591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and interferon alfa-2b
Number of subjects: 0
Study 8737099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ST segment monitoring
Number of subjects: 1067
Study 1426218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline
Number of subjects: 23
Study 1426218 — intervention group
Group type: COMPARATOR
Intervention: Intravenous terbutaline
Number of subjects: 23
Study 2861738 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 15
Study 2861738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31651973 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm
Number of subjects: 26525
Study 31651973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting algorithm
Number of subjects: 26525
Study 31651973 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression algorithm
Number of subjects: 26525
Study 31651973 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression, gradient boosting, and random forest algorithms
Number of subjects: 26525
Study 28505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust manipulation targeting the cervicothoracic junction
Number of subjects: 102
Study 28505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual stretch of the upper trapezius muscle
Number of subjects: 102
Study 28505955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 28505955 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust manipulation and stretching
Number of subjects: 102
Study 25280961 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading parameters (weight load size and frequency)
Number of subjects: 12
Study 25280961 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-load speed
Number of subjects: 12
Study 23404723 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL group (neurofeedback using near-infrared spectroscopy)
Number of subjects: 20
Study 23404723 — intervention group
Group type: COMPARATOR
Intervention: SHAM group (irrelevant randomized signals)
Number of subjects: 20
Study 21792552 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18
Study 21792552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19365719 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention by paraprofessionals
Number of subjects: 62
Study 19365719 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 62
Study 16685181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Treatment (EIBT)
Number of subjects: 21
Study 16685181 — intervention group
Group type: COMPARATOR
Intervention: Control (special education classes)
Number of subjects: 21
Study 15298879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen and compressed air (AIRc)
Number of subjects: 0
Study 15298879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen and nitrous oxide
Number of subjects: 0
Study 15298879 — intervention group
Group type: COMPARATOR
Intervention: Oxygen and synthetic air (AIRs)
Number of subjects: 0
Study 11737006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular needle insertions into six designated trigger points
Number of subjects: 15
Study 11737006 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insertions (Control)
Number of subjects: 15
Study 9008270 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (200 mg q 12h) for 3 days, followed by didanosine (200 mg q 12h) and ciprofloxacin (750 mg q 12h) for 3 days, and then another course of didanosine (200 mg q 12h for 3 days)
Number of subjects: 16
Study 9008270 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg q 12h) for 3 days, followed by the combination with didanosine, and then ciprofloxacin (750 mg q 12h for 3 days)
Number of subjects: 16
Study 8353827 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoprotiline (150 mg)
Number of subjects: 23
Study 8353827 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (150 mg)
Number of subjects: 23
Study 3621988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (1000 mg daily)
Number of subjects: 50
Study 3621988 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (750 mg daily)
Number of subjects: 50
Study 30274772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213
Study 30274772 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study 30274772 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (including Rivaroxaban)
Number of subjects: 7213
Study 27974114 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine pulmonary surfactant (PS) + budesonide suspension (0.25 mg/kg)
Number of subjects: 70
Study 24355814 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot-on formulation containing polyunsaturated fatty acids (PUFAs) and essential oils
Number of subjects: 48
Study 24355814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23868093 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring (8.3-mm thick Tarkett Omnisports EXCEL)
Number of subjects: 226
Study 23868093 — intervention group
Group type: COMPARATOR
Intervention: Standard in situ flooring (2-mm)
Number of subjects: 226
Study 19452177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 10
Number of subjects: 80
Study 19452177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 20
Number of subjects: 80
Study 19452177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 50
Number of subjects: 80
Study 19452177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 100
Number of subjects: 80
Study 19035110 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Care Simulator (ECS) combined with Problem-Based Learning (PBL)
Number of subjects: 42
Study 19035110 — intervention group
Group type: COMPARATOR
Intervention: Problem-Based Learning (PBL)
Number of subjects: 42
Study 16839405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Number of subjects: 50
Study 16839405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 50
Study 16839405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hydrolysed whey-based formula)
Number of subjects: 50
Study 14662234 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan for diagnosing appendicitis
Number of subjects: 0
Study 10780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg + Bezafibrate 400 mg
Number of subjects: 333
Study 10780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg
Number of subjects: 333
Study 10780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg + Bezafibrate 400 mg
Number of subjects: 333
Study 10780315 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg
Number of subjects: 333
Study 10780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Fluvastatin + Bezafibrate)
Number of subjects: 333
Study 8842353 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 303
Study 1296496 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiray 300 (ioversol)
Number of subjects: 0
Study 7049586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 47
Study 7049586 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 47
Study 31805295 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-catheter devices for treating tricuspid regurgitation
Number of subjects: 0
Study 31805295 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative trial designs for pivotal randomized trials
Number of subjects: 0
Study 30486814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutritional counselling intervention delivered via telephone
Number of subjects: 0
Study 30486814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutritional counselling intervention delivered via mobile application
Number of subjects: 0
Study 30486814 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection for 14 days (IE-Tr)
Number of subjects: 204
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection for 14 days (ES-Tr)
Number of subjects: 204
Study 26814241 — intervention group
Group type: COMPARATOR
Intervention: Control group (IE-Ctl)
Number of subjects: 204
Study 26814241 — intervention group
Group type: COMPARATOR
Intervention: Control group (ES-Ctl)
Number of subjects: 204
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (ES-Tr)
Number of subjects: 204
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (IE-Tr)
Number of subjects: 204
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (IE-Tr and ES-Tr)
Number of subjects: 204
Study 26814241 — intervention group
Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia incidence
Number of subjects: 204
Study 24411005 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) with 30 seconds exposure duration
Number of subjects: 5
Study 24411005 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) with 1 minute exposure duration
Number of subjects: 5
Study 18444724 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid disorders during adolescence
Number of subjects: 80
Study 18444724 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing and externalizing disorders
Number of subjects: 80
Study 18444724 — intervention group
Group type: EXPERIMENTAL
Intervention: More internalizing diagnoses
Number of subjects: 80
Study 18444724 — intervention group
Group type: EXPERIMENTAL
Intervention: More externalizing disorders
Number of subjects: 80
Study 18444724 — intervention group
Group type: EXPERIMENTAL
Intervention: More internalizing diagnoses for females
Number of subjects: 80
Study 15719856 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cmH2O of PEEP to the dependent lung during one-lung ventilation
Number of subjects: 46
Study 15719856 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 46
Study 11323542 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment (twice a day ferrous iron, equivalent to 2 x 100 mg elemental iron)
Number of subjects: 40
Study 11323542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11323542 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 40
Study 9466092 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 596
Study 9466092 — intervention group
Group type: COMPARATOR
Intervention: S-CMV
Number of subjects: 596
Study 9466092 — intervention group
Group type: COMPARATOR
Intervention: S-IMV
Number of subjects: 596
Study 8187302 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 12 hours prior to GHRH
Number of subjects: 24
Study 8187302 — intervention group
Group type: COMPARATOR
Intervention: Placebo 12 hours prior to GHRH
Number of subjects: 24
Study 8187302 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 8 hours prior to GHRH
Number of subjects: 24
Study 8187302 — intervention group
Group type: COMPARATOR
Intervention: Placebo 8 hours prior to GHRH
Number of subjects: 24
Study 8187302 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 16 hours prior to GHRH
Number of subjects: 24
Study 8187302 — intervention group
Group type: COMPARATOR
Intervention: Placebo 16 hours prior to GHRH
Number of subjects: 24
Study 3285832 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg torasemide
Number of subjects: 111
Study 3285832 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg torasemide
Number of subjects: 111
Study 3285832 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg torasemide (increased to 20 mg)
Number of subjects: 111
Study 3285832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 111
Study 11425972 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body PET with fluorine 18 alpha-methyl tyrosine (FMT)
Number of subjects: 24
Study 11425972 — intervention group
Group type: COMPARATOR
Intervention: Whole-body PET with 2‐[fluorine 18]fluoro‐2‐deoxy‐D‐glucose (FDG)
Number of subjects: 24
Study 29573269 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home laparoscopic simulator training program (2015)
Number of subjects: 33
Study 29573269 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home laparoscopic simulator training program (2016)
Number of subjects: 33
Study 29573269 — intervention group
Group type: COMPARATOR
Intervention: Take-home laparoscopic simulator training program
Number of subjects: 33
Study 29432518 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual structured medication reviews by physician, pharmacist, and nurse.
Number of subjects: 380
Study 29432518 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 380
Study 27094338 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic skills training message
Number of subjects: 181
Study 27094338 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical/technical skills training message
Number of subjects: 181
Study 25130998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg)
Number of subjects: 455
Study 25130998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg)
Number of subjects: 455
Study 25130998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Trastuzumab (lapatinib 1000 mg, trastuzumab same dose as single agent)
Number of subjects: 455
Study 25130998 — intervention group
Group type: COMPARATOR
Intervention: Pathological complete response
Number of subjects: 455
Study 22720689 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of gentamicin in combination with metronidazole 30 to 60 minutes prior to operation
Number of subjects: 490
Study 22720689 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of gentamicin and metronidazole for 24 hours post-operation
Number of subjects: 490
Study 20441408 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17OHPC)
Number of subjects: 221
Study 20441408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 18540851 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15951466 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414 (0.625-12.5 mg/kg)
Number of subjects: 64
Study 15951466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11823009 — intervention group
Group type: EXPERIMENTAL
Intervention: PBNT with non-rinse conditioner (NRC)
Number of subjects: 0
Study 11823009 — intervention group
Group type: COMPARATOR
Intervention: Thermocycling regimens
Number of subjects: 0
Study 11823009 — intervention group
Group type: COMPARATOR
Intervention: Polished and fractured specimens
Number of subjects: 0
Study 10069912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline with lidocaine (LIDO)
Number of subjects: 42
Study 10069912 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline alone (HS)
Number of subjects: 42
Study 10069912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LIDO and HS)
Number of subjects: 42
Study 7562241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) at low dose (5 mg/kg/day)
Number of subjects: 107
Study 7562241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) at high dose (10 mg/kg/day)
Number of subjects: 107
Study 7562241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) during tapering to lower doses
Number of subjects: 107
Study 2109330 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 in oxygen inhalation
Number of subjects: 50
Study 2109330 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (placebo control)
Number of subjects: 50
Study 6791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous injection of synthetic salmon calcitonin (2-200 i.u.)
Number of subjects: 21
Study 6791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of synthetic salmon calcitonin (10-200 i.u. thrice weekly for up to 2 months)
Number of subjects: 21
Study 6791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of synthetic salmon calcitonin
Number of subjects: 21
Study 6791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium absorption (six studies) during treatment
Number of subjects: 21
Study 31825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic songwriting intervention
Number of subjects: 132
Study 31825266 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study 31261260 — intervention group
Group type: COMPARATOR
Intervention: 5° Trendelenburg positioning
Number of subjects: 50
Study 31261260 — intervention group
Group type: COMPARATOR
Intervention: 10° Trendelenburg positioning
Number of subjects: 50
Study 31261260 — intervention group
Group type: COMPARATOR
Intervention: 15° Trendelenburg positioning
Number of subjects: 50
Study 27981804 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-Logic closed-loop system
Number of subjects: 75
Study 27981804 — intervention group
Group type: COMPARATOR
Intervention: SAP therapy
Number of subjects: 75
Study 26547349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg loading dose, followed by 0.3 µg·kg(‐1)·h(‐1) continuous infusion)
Number of subjects: 60
Study 26547349 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 60
Study 24371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 40 mg/day
Number of subjects: 725
Study 24371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 60 mg/day
Number of subjects: 725
Study 24371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 80 mg/day
Number of subjects: 725
Study 24371021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 24371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) (all doses combined)
Number of subjects: 725
Study 22954329 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with locking plates for two-part fractures
Number of subjects: 0
Study 22954329 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for two-part fractures
Number of subjects: 0
Study 22954329 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with Philos locking plate for multi-fragmented fractures
Number of subjects: 0
Study 22954329 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty with Epoca prosthesis for multi-fragmented fractures
Number of subjects: 0
Study 22954329 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for multi-fragmented fractures
Number of subjects: 0
Study 19104193 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program for nurses (2 days, 33 hours)
Number of subjects: 413
Study 17700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (G III)
Number of subjects: 64
Study 17700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (G IV)
Number of subjects: 64
Study 17700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (G II)
Number of subjects: 64
Study 17700217 — intervention group
Group type: EXPERIMENTAL
Intervention: No intervention (G I)
Number of subjects: 64
Study 15334764 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-reducing filter (LRF)
Number of subjects: 17
Study 15334764 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB circuit with no LRF (Control)
Number of subjects: 17
Study 11600559 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended fasting
Number of subjects: 0
Study 11600559 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion (5.8-6.5 mmol/liter)
Number of subjects: 0
Study 11600559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of glucose infusion (up to 8.7 mmol/liter)
Number of subjects: 0
Study 11600559 — intervention group
Group type: EXPERIMENTAL
Intervention: All levels of glycemia
Number of subjects: 0
Study 9641801 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pulse stimuli
Number of subjects: 48
Study 9641801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse stimuli
Number of subjects: 48